Strategic consulting firm Blue Matter is boosting its communications digs with the acquisition of global healthcare communications agency Cognite.
With a tagline of “bringing science to life,” Cognite primarily focuses on complex specialty markets such as rare diseases and offers services across commercial, medical, corporate and patient communications. Blue Matter, meanwhile, is a “valuable strategic resource and a thought leader” in biopharma portfolio, product and functional strategy,” CEO Ashwin Dandekar commented in an Oct. 28 press release.
The firm has been “systemically bringing together” important communications and creative capabilities over the past few years to support its strategies with providers, payers, patients and other stakeholders, making Cognite’s “array of capabilities, creativity and team culture” a “perfect fit for the Blue Matter family,” Dandekar added.
Cognite houses its worldwide array of offices and people in London, England; Zug, Switzerland; and Boston, U.S., and looks to take its communications skills to a “far wider audience” as part of Blue Matter, its CEO Lee Hurley noted in a statement, pointing to the “tremendous opportunities for growth” stemming from the merger.
“Our last decade of growth has demonstrated the appetite and belief in our proposition and how to deliver it,” Cognite’s chief business officer Sean Cush added. “Our focus on transformative medicines and the complex diseases they tackle is now something we can turbocharge by joining Blue Matter, harnessing world-class strategic capabilities, empowering technologies, and gaining true global reach.”
No financial terms were disclosed for the deal. Blue Matter is a portfolio company of global private equity Biard Capital.
While the M&A landscape across healthcare agencies has been hot recently, recent deals have largely focused on integrating AI and emerging tech capabilities. Eversana, for one, dove deeper into the global AI services pool with its Oct. 28 buy of London-based health economics and outcomes research (HEOR) company Estima Scientific, while CG Life picked up AI-native agency The Considered + AI over the summer.